Tissue Regenix Group PLC (LON:TRX) shares hit a new 52-week low during trading on Tuesday . The stock traded as low as GBX 9.75 ($0.13) and last traded at GBX 9.75 ($0.13), with a volume of 329,270 shares trading hands. The stock had previously closed at GBX 10.50 ($0.14).

Separately, Jefferies Group LLC reissued a “buy” rating and set a GBX 39 ($0.52) price target on shares of Tissue Regenix Group PLC in a research report on Friday, July 21st.

The company’s market capitalization is GBX 71.32 million. The company’s 50-day moving average is GBX 12.00 and its 200 day moving average is GBX 13.44.

In related news, insider John Andrew Samuel acquired 2,000,000 shares of the firm’s stock in a transaction on Wednesday, August 9th. The stock was purchased at an average cost of GBX 10 ($0.13) per share, with a total value of £200,000 ($265,745.42).

TRADEMARK VIOLATION NOTICE: This piece of content was published by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.watchlistnews.com/tissue-regenix-group-plc-trx-reaches-new-12-month-low-at-9-75/1639902.html.

About Tissue Regenix Group PLC

Tissue Regenix Group plc is a medical technology company. The Company is engaged in the development of regenerative products to make replacement native tissue using biological (human and animal) tissues. It operates through Cardiac, Wound Care and Orthopaedics divisions. Its decellularisation (dCELL) technology removes deoxyribonucleic acid and other cellular material from tissue leaving an acellular scaffold, which is not rejected by the patient’s body.

Receive News & Ratings for Tissue Regenix Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tissue Regenix Group PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.